Weight-loss pharmacology has a history — and a cautionary one
From 2,4-Dinitrophenol (banned 1938) to Fen-Phen (withdrawn 1997) to lorcaserin (withdrawn 2020), the market has repeatedly seen effective drugs pulled for safety. Each withdrawal changed how regulators evaluate obesity medications — and why today's approvals demand cardiovascular outcome data.
| Medication Name | Biological Mechanism of Action | Reported Efficacy | Primary Safety / Adverse Events | Year of Withdrawal / Action Taken | Source |
|---|---|---|---|---|---|
| Lorcaserin (Belviq) | 5-HT2C receptor agonist | 3.3% to 6.25% (placebo-subtracted) | Increased risk of cancer | Withdrawn 2019/ | 2, 3, Inferred, Wikipedia Withdrawn Medications |
| Sibutramine (Meridia) | Serotonin–norepinephrine reuptake inhibitor | 4.3% to 19.7% (~4.3–4.5 kg / 9.5 lbs) | Cardiovascular events, including increased risk of heart attack and stroke | Withdrawn | 2, 3, 4, Inferred, Wikipedia Withdrawn Medications |
| Rimonabant (Acomplia) | Cannabinoid receptor (CB1) antagonist | 13.9% (2.6 to 6.3 kg / 5.7 to 13.9 lbs) | Severe psychiatric disturbances and suicide risks | Withdrawn 2008/ | 2, 3, Inferred, Wikipedia Withdrawn Medications |
| Fenfluramine / Phentermine (Fen-Phen) | Serotonergic releasing agent / Sympathomimetic amine | 13.9% to 15% (~15 to 17.1 lbs / 7.7 kg) | Valvular heart disease and pulmonary hypertension | Withdrawn | 2, 3, Inferred, Wikipedia Withdrawn Medications |
| 2,4-Dinitrophenol (DNP) | Mitochondrial uncoupling agent | Rapid weight loss (~1.5 kg per week / 17.1 lbs average) | Fatal hyperthermia, cataracts, and multi-organ failure | Banned | 2, 3, Inferred, Wikipedia Withdrawn Medications |
| Ephedra | Sympathomimetic (alpha and beta adrenergic agonist) | 0.6 to 0.9 kg (2.0 lbs) per month more than placebo | Cardiovascular events, stroke, seizures, and fatal outcomes | Banned | 2, 3, Inferred, Wikipedia Withdrawn Medications |
| Dexfenfluramine (Redux) | Serotonin releasing agent | 3.5 kg (7.7 lbs) | Valvular heart disease | Withdrawn | |
| Fenfluramine (Pondimin) | Serotonin releasing agent | Not in source | Valvular heart disease | Withdrawn | |
| Phenylpropanolamine | Not in source | 1.5 kg (3.3 lbs) | Risk of hemorrhagic stroke | Withdrawn | |
| Amphetamine salts (Obetrol) | Not in source | Not in source | Mental disturbances, cardiac side effects, and drug dependence | Withdrawn |
Why this history matters now
The modern GLP-1 generation was approved with cardiovascular-outcome trials — a direct response to the sibutramine and fenfluramine disasters. When you see a headline about a new weight-loss drug, this table is the context: efficacy was never the problem in the past; long-term safety was.
The short version
- From 2,4-Dinitrophenol, banned in 1938, to Fen-Phen and then lorcaserin, the article traces a history of effective weight-loss drugs pulled from the market for safety.
- Lorcaserin (Belviq), a 5-HT2C receptor agonist with 3.3 to 6.25 percent placebo-subtracted efficacy, was withdrawn over an increased risk of cancer.
- Fen-Phen, combining fenfluramine and phentermine, delivered 13.9 to 15 percent weight loss, roughly 7.7 kg, but caused valvular heart disease and pulmonary hypertension.
- DNP worked as a mitochondrial uncoupling agent producing about 1.5 kg of loss per week but caused fatal hyperthermia, cataracts, and multi-organ failure, and ephedra was banned after cardiovascular events, strokes, seizures, and deaths.
- Dexfenfluramine (Redux) at 3.5 kg, phenylpropanolamine at 1.5 kg with hemorrhagic stroke risk, and amphetamine salts with dependence and cardiac effects round out the withdrawn list.
- The article's point is that efficacy was never the problem in the past, long-term safety was, which is why modern GLP-1 drugs were approved with cardiovascular-outcome trials.
The practical takeaway
Use approved medications under medical supervision, report side effects, and treat "miracle" claims with the skepticism this history justifies. Get matched with a provider who follows the evidence — past and present.
